Edwards Lifesciences Corporation (EW)
USD 72.81
(-1.77%)
USD 72.81
(-1.77%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 6 Billion USD | 11.56% |
| 2022 | 5.38 Billion USD | 2.86% |
| 2021 | 5.23 Billion USD | 19.29% |
| 2020 | 4.38 Billion USD | 0.88% |
| 2019 | 4.34 Billion USD | 16.79% |
| 2018 | 3.72 Billion USD | 8.37% |
| 2017 | 3.43 Billion USD | 15.91% |
| 2016 | 2.96 Billion USD | 18.85% |
| 2015 | 2.49 Billion USD | 7.35% |
| 2014 | 2.32 Billion USD | 13.56% |
| 2013 | 2.04 Billion USD | 7.68% |
| 2012 | 1.89 Billion USD | 13.17% |
| 2011 | 1.67 Billion USD | 16.01% |
| 2010 | 1.44 Billion USD | 9.51% |
| 2009 | 1.32 Billion USD | 6.76% |
| 2008 | 1.23 Billion USD | 13.44% |
| 2007 | 1.09 Billion USD | 5.22% |
| 2006 | 1.03 Billion USD | 3.92% |
| 2005 | 997.9 Million USD | 7.13% |
| 2004 | 931.5 Million USD | 8.25% |
| 2003 | 860.5 Million USD | 22.23% |
| 2002 | 704 Million USD | 1.73% |
| 2001 | 692 Million USD | -13.93% |
| 2000 | 804 Million USD | -11.16% |
| 1999 | 905 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.59 Billion USD | 4.18% |
| 2024 Q3 | 1.35 Billion USD | -2.27% |
| 2024 Q2 | 1.38 Billion USD | -13.28% |
| 2023 Q3 | 1.48 Billion USD | -3.22% |
| 2023 Q4 | 1.53 Billion USD | 3.59% |
| 2023 FY | 6 Billion USD | 11.56% |
| 2023 Q1 | 1.45 Billion USD | 8.25% |
| 2023 Q2 | 1.53 Billion USD | 4.84% |
| 2022 Q1 | 1.34 Billion USD | 0.86% |
| 2022 FY | 5.38 Billion USD | 2.86% |
| 2022 Q3 | 1.31 Billion USD | -4.0% |
| 2022 Q2 | 1.37 Billion USD | 2.44% |
| 2022 Q4 | 1.34 Billion USD | 2.22% |
| 2021 FY | 5.23 Billion USD | 19.29% |
| 2021 Q1 | 1.21 Billion USD | 2.09% |
| 2021 Q3 | 1.31 Billion USD | -4.78% |
| 2021 Q2 | 1.37 Billion USD | 13.1% |
| 2021 Q4 | 1.32 Billion USD | 1.49% |
| 2020 Q2 | 925 Million USD | -18.05% |
| 2020 Q1 | 1.12 Billion USD | -3.87% |
| 2020 Q4 | 1.19 Billion USD | 4.45% |
| 2020 Q3 | 1.14 Billion USD | 23.34% |
| 2020 FY | 4.38 Billion USD | 0.88% |
| 2019 Q4 | 1.17 Billion USD | 7.32% |
| 2019 Q1 | 993 Million USD | 1.56% |
| 2019 Q2 | 1.08 Billion USD | 9.46% |
| 2019 Q3 | 1.09 Billion USD | 0.65% |
| 2019 FY | 4.34 Billion USD | 16.79% |
| 2018 Q3 | 906.6 Million USD | -3.93% |
| 2018 FY | 3.72 Billion USD | 8.37% |
| 2018 Q2 | 943.7 Million USD | 5.46% |
| 2018 Q1 | 894.8 Million USD | 0.71% |
| 2018 Q4 | 977.7 Million USD | 7.84% |
| 2017 Q1 | 883.5 Million USD | 15.08% |
| 2017 FY | 3.43 Billion USD | 15.91% |
| 2017 Q4 | 888.5 Million USD | 8.16% |
| 2017 Q2 | 841.8 Million USD | -4.72% |
| 2017 Q3 | 821.5 Million USD | -2.41% |
| 2016 Q3 | 739.4 Million USD | -2.62% |
| 2016 Q2 | 759.3 Million USD | 8.89% |
| 2016 Q4 | 767.7 Million USD | 3.83% |
| 2016 Q1 | 697.3 Million USD | 3.9% |
| 2016 FY | 2.96 Billion USD | 18.85% |
| 2015 FY | 2.49 Billion USD | 7.35% |
| 2015 Q4 | 671.1 Million USD | 9.03% |
| 2015 Q2 | 616.8 Million USD | 4.49% |
| 2015 Q3 | 615.5 Million USD | -0.21% |
| 2015 Q1 | 590.3 Million USD | -4.48% |
| 2014 Q4 | 618 Million USD | 1.75% |
| 2014 Q3 | 607.4 Million USD | 5.62% |
| 2014 FY | 2.32 Billion USD | 13.56% |
| 2014 Q2 | 575.1 Million USD | 10.09% |
| 2014 Q1 | 522.4 Million USD | -2.54% |
| 2013 Q2 | 517.2 Million USD | 4.13% |
| 2013 FY | 2.04 Billion USD | 7.68% |
| 2013 Q4 | 536 Million USD | 8.15% |
| 2013 Q3 | 495.6 Million USD | -4.18% |
| 2013 Q1 | 496.7 Million USD | -2.7% |
| 2012 Q2 | 482 Million USD | 4.97% |
| 2012 Q1 | 459.2 Million USD | 6.74% |
| 2012 Q3 | 447.9 Million USD | -7.07% |
| 2012 FY | 1.89 Billion USD | 13.17% |
| 2012 Q4 | 510.5 Million USD | 13.98% |
| 2011 Q3 | 412.7 Million USD | -4.29% |
| 2011 Q4 | 430.2 Million USD | 4.24% |
| 2011 Q1 | 404.5 Million USD | 3.08% |
| 2011 FY | 1.67 Billion USD | 16.01% |
| 2011 Q2 | 431.2 Million USD | 6.6% |
| 2010 Q4 | 392.4 Million USD | 12.47% |
| 2010 FY | 1.44 Billion USD | 9.51% |
| 2010 Q1 | 340.5 Million USD | -1.79% |
| 2010 Q2 | 365.2 Million USD | 7.25% |
| 2010 Q3 | 348.9 Million USD | -4.46% |
| 2009 FY | 1.32 Billion USD | 6.76% |
| 2009 Q4 | 346.7 Million USD | 6.45% |
| 2009 Q3 | 325.7 Million USD | -2.92% |
| 2009 Q2 | 335.5 Million USD | 7.02% |
| 2009 Q1 | 313.5 Million USD | 1.23% |
| 2008 Q2 | 327.6 Million USD | 10.38% |
| 2008 FY | 1.23 Billion USD | 13.44% |
| 2008 Q4 | 309.7 Million USD | 2.01% |
| 2008 Q3 | 303.6 Million USD | -7.33% |
| 2008 Q1 | 296.8 Million USD | 1.3% |
| 2007 Q2 | 272.6 Million USD | 3.22% |
| 2007 Q3 | 261.4 Million USD | -4.11% |
| 2007 Q1 | 264.1 Million USD | -0.56% |
| 2007 Q4 | 293 Million USD | 12.09% |
| 2007 FY | 1.09 Billion USD | 5.22% |
| 2006 Q1 | 257 Million USD | 2.92% |
| 2006 Q2 | 267.3 Million USD | 4.01% |
| 2006 FY | 1.03 Billion USD | 3.92% |
| 2006 Q3 | 247.4 Million USD | -7.44% |
| 2006 Q4 | 265.6 Million USD | 7.36% |
| 2005 Q4 | 249.7 Million USD | 3.65% |
| 2005 Q1 | 249.1 Million USD | 5.06% |
| 2005 Q2 | 258.2 Million USD | 3.65% |
| 2005 Q3 | 240.9 Million USD | -6.7% |
| 2005 FY | 997.9 Million USD | 7.13% |
| 2004 Q2 | 234.6 Million USD | -0.17% |
| 2004 FY | 931.5 Million USD | 8.25% |
| 2004 Q4 | 237.1 Million USD | 5.47% |
| 2004 Q3 | 224.8 Million USD | -4.18% |
| 2004 Q1 | 235 Million USD | 4.86% |
| 2003 Q4 | 224.1 Million USD | 8.73% |
| 2003 Q1 | 212.5 Million USD | 4.63% |
| 2003 Q2 | 217.8 Million USD | 2.49% |
| 2003 Q3 | 206.1 Million USD | -5.37% |
| 2003 FY | 860.5 Million USD | 22.23% |
| 2002 FY | 704 Million USD | 1.73% |
| 2002 Q2 | 172.8 Million USD | 6.47% |
| 2002 Q4 | 203.1 Million USD | 22.5% |
| 2002 Q3 | 165.8 Million USD | -4.05% |
| 2002 Q1 | 162.3 Million USD | 1.5% |
| 2001 Q2 | 192.4 Million USD | 0.26% |
| 2001 Q3 | 147.8 Million USD | -23.18% |
| 2001 FY | 692 Million USD | -13.93% |
| 2001 Q4 | 159.9 Million USD | 8.19% |
| 2001 Q1 | 191.9 Million USD | -11.36% |
| 2000 FY | 804 Million USD | -11.16% |
| 2000 Q1 | 226 Million USD | -3.42% |
| 2000 Q2 | 205 Million USD | -9.29% |
| 2000 Q3 | 185.8 Million USD | -9.37% |
| 2000 Q4 | 216.5 Million USD | 16.52% |
| 1999 FY | 905 Million USD | 0.0% |
| 1999 Q4 | 234 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Abbott Laboratories | 40.1 Billion USD | 85.029% |
| Allurion Technologies Inc. | 53.46 Million USD | -11130.853% |
| Artivion, Inc. | 354 Million USD | -1596.252% |
| Avanos Medical, Inc. | 673.3 Million USD | -791.846% |
| Butterfly Network, Inc. | 65.9 Million USD | -9011.988% |
| Butterfly Network, Inc. | 65.9 Million USD | -9011.988% |
| Bio-Rad Laboratories, Inc. | 2.67 Billion USD | -124.793% |
| Boston Scientific Corporation | 14.24 Billion USD | 57.831% |
| Perspective Therapeutics, Inc. | 7.1 Million USD | -84427.027% |
| CONMED Corporation | 1.24 Billion USD | -383.886% |
| Paragon 28, Inc. | 216.38 Million USD | -2675.002% |
| Glaukos Corporation | 314.71 Million USD | -1808.036% |
| Globus Medical, Inc. | 1.56 Billion USD | -282.843% |
| Inspire Medical Systems, Inc. | 624.79 Million USD | -861.077% |
| Integer Holdings Corporation | 1.59 Billion USD | -276.082% |
| Medtronic plc | 32.36 Billion USD | 81.446% |
| Nevro Corp. | 425.17 Million USD | -1312.316% |
| Owlet, Inc. | 54.01 Million USD | -11017.941% |
| Penumbra, Inc. | 1.05 Billion USD | -467.282% |
| Vicarious Surgical Inc. | - USD | -Infinity% |
| Smith & Nephew plc | 5.54 Billion USD | -8.214% |
| Sonendo, Inc. | 43.86 Million USD | -13589.274% |
| STERIS plc | 5.13 Billion USD | -16.854% |
| Stryker Corporation | 20.49 Billion USD | 70.705% |
| Vapotherm, Inc. | 68.66 Million USD | -8644.557% |
| Zimmer Biomet Holdings, Inc. | 7.39 Billion USD | 18.79% |